113 related articles for article (PubMed ID: 1862547)
1. Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients.
Lissoni P; Barni S; Rovelli F; Crispino S; Fumagalli G; Pescia S; Vaghi M; Camesasca G; Tancini G
Tumori; 1991 Jun; 77(3):212-5. PubMed ID: 1862547
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
[TBL] [Abstract][Full Text] [Related]
3. Acute endocrine effects of interleukin-12 in cancer patients.
Lissoni P; Rovelli F; Rivolta MR; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G
J Biol Regul Homeost Agents; 1997; 11(4):154-6. PubMed ID: 9582616
[TBL] [Abstract][Full Text] [Related]
4. Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Barni S; Lissoni P; Tancini G; Crispino S; Paolorossi F; Rovelli F; Fumagalli G; Ferri L; Esposti D; Esposti G
Tumori; 1987 Apr; 73(2):181-5. PubMed ID: 2953096
[TBL] [Abstract][Full Text] [Related]
5. Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients.
Spinazzé S; Viviani S; Bidoli P; Rovelli F; Palmer P; Franks CR; Arienti F; Rivoltini L; Parmiani G
Tumori; 1991 Dec; 77(6):496-9. PubMed ID: 1666467
[TBL] [Abstract][Full Text] [Related]
6. Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)-beta in patients with chronic hepatitis C.
Ohno Y; Fujimoto M; Nishimura A; Aoki N
J Clin Endocrinol Metab; 1998 Oct; 83(10):3681-7. PubMed ID: 9768684
[TBL] [Abstract][Full Text] [Related]
7. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol.
Waldhauser F; Lieberman HR; Lynch HJ; Waldhauser M; Herkner K; Frisch H; Vierhapper H; Waldhäusl W; Schemper M; Wurtman RJ
Neuroendocrinology; 1987 Aug; 46(2):125-30. PubMed ID: 3114663
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of human recombinant interleukin-3 in cancer patients.
Lissoni P; Rovelli F; Tisi E; Ardizzoia A; Perlangeli V; Barni S; Tancini G
Int J Biol Markers; 1992; 7(4):230-3. PubMed ID: 1337088
[TBL] [Abstract][Full Text] [Related]
9. Effect of an acute injection of melatonin on the basal secretion of hypophyseal hormones in prepubertal and pubertal healthy subjects.
Lisoni P; Resentini M; Mauri R; De Medici C; Morabito F; Esposti D; Di Bella L; Esposti G; Rossi D; Parravicini L
Acta Endocrinol (Copenh); 1986 Mar; 111(3):305-11. PubMed ID: 3083625
[TBL] [Abstract][Full Text] [Related]
10. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients.
Viviani S; Bidoli P; Spinazzé S; Rovelli F; Lissoni P
J Pineal Res; 1992 Apr; 12(3):114-7. PubMed ID: 1324306
[TBL] [Abstract][Full Text] [Related]
11. Circadian and ultradian variations of pituitary and pineal hormones in normal men: evidence for a link between melatonin, gonadotropin, and prolactin secretion.
Lerchl A; Partsch CJ; Nieschlag E
J Pineal Res; 1995 Jan; 18(1):41-8. PubMed ID: 7776178
[TBL] [Abstract][Full Text] [Related]
12. Increase in plasma melatonin, beta-endorphin, and cortisol after a 28.5-mile mountain race: relationship to performance and lack of effect of naltrexone.
Strassman RJ; Appenzeller O; Lewy AJ; Qualls CR; Peake GT
J Clin Endocrinol Metab; 1989 Sep; 69(3):540-5. PubMed ID: 2527243
[TBL] [Abstract][Full Text] [Related]
13. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man.
Jezova D; Vigas M
Psychoneuroendocrinology; 1988; 13(6):479-85. PubMed ID: 2853401
[TBL] [Abstract][Full Text] [Related]
16. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
[TBL] [Abstract][Full Text] [Related]
17. A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Esposti D; Lissoni P; Tancini G; Barni S; Crispino S; Paolorossi F; Rovelli F; Ferri L; Cattaneo G; Esposti G
Cancer; 1988 Aug; 62(3):494-9. PubMed ID: 2968835
[TBL] [Abstract][Full Text] [Related]
18. Effect of melatonin treatment on 24-hour rhythms of serum ACTH, growth hormone, prolactin, luteinizing hormone and insulin in rats injected with Freund's adjuvant.
Esquifino AI; Castrillón P; García-Bonacho M; Vara E; Cardinali DP
J Pineal Res; 1999 Aug; 27(1):15-23. PubMed ID: 10451020
[TBL] [Abstract][Full Text] [Related]
19. The neuroendocrine effects of interleukin-2 treatment.
Denicoff KD; Durkin TM; Lotze MT; Quinlan PE; Davis CL; Listwak SJ; Rosenberg SA; Rubinow DR
J Clin Endocrinol Metab; 1989 Aug; 69(2):402-10. PubMed ID: 2546965
[TBL] [Abstract][Full Text] [Related]
20. Alpha-melanocyte-stimulating hormone antagonizes the neuroendocrine effects of corticotropin-releasing factor and interleukin-1 alpha in the primate.
Shalts E; Feng YJ; Ferin M; Wardlaw SL
Endocrinology; 1992 Jul; 131(1):132-8. PubMed ID: 1319315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
